Omeros Receives Negative CHMP Opinion on Narsoplimab Application
The EMA’s CHMP issued a negative opinion on Omeros’ marketing authorization application for narsoplimab following re-examination.
Omeros Corporation (NASDAQ:OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell tr…